vs

Side-by-side financial comparison of Cardlytics, Inc. (CDLX) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $50.9M, roughly 1.5× Cardlytics, Inc.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -25.5%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $13.0M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -9.6%).

Cardlytics is a leading purchase intelligence and advertising platform that partners with major banks to analyze anonymized consumer transaction data. It delivers targeted, performance-driven ad campaigns for consumer brands, retailers and service providers, helping advertisers reach audiences based on real purchase behavior, with core operations across North America and the United Kingdom.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

CDLX vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.5× larger
PBYI
$75.5M
$50.9M
CDLX
Growing faster (revenue YoY)
PBYI
PBYI
+53.2% gap
PBYI
27.7%
-25.5%
CDLX
More free cash flow
PBYI
PBYI
$1.4M more FCF
PBYI
$14.4M
$13.0M
CDLX
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
-9.6%
CDLX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CDLX
CDLX
PBYI
PBYI
Revenue
$50.9M
$75.5M
Net Profit
Gross Margin
69.3%
Operating Margin
-12.0%
22.7%
Net Margin
Revenue YoY
-25.5%
27.7%
Net Profit YoY
EPS (diluted)
$-0.15
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDLX
CDLX
PBYI
PBYI
Q4 25
$50.9M
$75.5M
Q3 25
$47.0M
$54.5M
Q2 25
$58.0M
$52.4M
Q1 25
$56.4M
$46.0M
Q4 24
$68.3M
$59.1M
Q3 24
$61.1M
$80.5M
Q2 24
$64.0M
$47.1M
Q1 24
$62.2M
$43.8M
Net Profit
CDLX
CDLX
PBYI
PBYI
Q4 25
Q3 25
$-72.7M
$8.8M
Q2 25
$-9.3M
$5.9M
Q1 25
$-13.3M
$3.0M
Q4 24
Q3 24
$-145.2M
$20.3M
Q2 24
$-4.3M
$-4.5M
Q1 24
$-24.3M
$-4.8M
Gross Margin
CDLX
CDLX
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
CDLX
CDLX
PBYI
PBYI
Q4 25
-12.0%
22.7%
Q3 25
-146.6%
17.6%
Q2 25
-22.0%
12.7%
Q1 25
-24.9%
8.7%
Q4 24
-12.2%
22.6%
Q3 24
-243.1%
27.4%
Q2 24
-24.7%
-4.6%
Q1 24
-36.7%
-5.3%
Net Margin
CDLX
CDLX
PBYI
PBYI
Q4 25
Q3 25
-154.7%
16.2%
Q2 25
-16.0%
11.2%
Q1 25
-23.5%
6.5%
Q4 24
Q3 24
-237.6%
25.2%
Q2 24
-6.7%
-9.6%
Q1 24
-39.0%
-11.0%
EPS (diluted)
CDLX
CDLX
PBYI
PBYI
Q4 25
$-0.15
$0.26
Q3 25
$-1.36
$0.17
Q2 25
$-0.18
$0.12
Q1 25
$-0.26
$0.06
Q4 24
$-0.36
$0.40
Q3 24
$-2.90
$0.41
Q2 24
$-0.09
$-0.09
Q1 24
$-0.56
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDLX
CDLX
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$48.7M
$97.5M
Total DebtLower is stronger
$212.6M
$22.7M
Stockholders' EquityBook value
$-6.5M
$130.3M
Total Assets
$285.6M
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDLX
CDLX
PBYI
PBYI
Q4 25
$48.7M
$97.5M
Q3 25
$44.0M
$94.4M
Q2 25
$46.7M
$96.0M
Q1 25
$52.0M
$93.2M
Q4 24
$65.6M
$101.0M
Q3 24
$67.0M
$96.7M
Q2 24
$71.2M
$96.8M
Q1 24
$97.8M
$107.2M
Total Debt
CDLX
CDLX
PBYI
PBYI
Q4 25
$212.6M
$22.7M
Q3 25
$214.6M
$34.0M
Q2 25
$214.3M
$45.3M
Q1 25
$213.9M
$56.7M
Q4 24
$213.6M
$68.0M
Q3 24
$213.2M
$79.3M
Q2 24
$212.9M
$90.7M
Q1 24
$257.9M
$102.0M
Stockholders' Equity
CDLX
CDLX
PBYI
PBYI
Q4 25
$-6.5M
$130.3M
Q3 25
$-4.7M
$115.3M
Q2 25
$58.7M
$104.7M
Q1 25
$64.1M
$97.1M
Q4 24
$70.0M
$92.1M
Q3 24
$69.7M
$71.1M
Q2 24
$210.0M
$48.5M
Q1 24
$199.1M
$51.0M
Total Assets
CDLX
CDLX
PBYI
PBYI
Q4 25
$285.6M
$216.3M
Q3 25
$292.8M
$202.9M
Q2 25
$361.1M
$194.9M
Q1 25
$369.1M
$196.2M
Q4 24
$392.7M
$213.3M
Q3 24
$399.4M
$220.7M
Q2 24
$534.4M
$205.0M
Q1 24
$569.0M
$214.1M
Debt / Equity
CDLX
CDLX
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
3.65×
0.43×
Q1 25
3.34×
0.58×
Q4 24
3.05×
0.74×
Q3 24
3.06×
1.12×
Q2 24
1.01×
1.87×
Q1 24
1.29×
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDLX
CDLX
PBYI
PBYI
Operating Cash FlowLast quarter
$13.0M
$14.4M
Free Cash FlowOCF − Capex
$13.0M
$14.4M
FCF MarginFCF / Revenue
25.5%
19.1%
Capex IntensityCapex / Revenue
0.0%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$8.8M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDLX
CDLX
PBYI
PBYI
Q4 25
$13.0M
$14.4M
Q3 25
$1.8M
$9.7M
Q2 25
$1.2M
$14.1M
Q1 25
$-6.7M
$3.6M
Q4 24
$3.0M
$15.6M
Q3 24
$1.4M
$11.0M
Q2 24
$4.4M
$1.0M
Q1 24
$-17.6M
$11.2M
Free Cash Flow
CDLX
CDLX
PBYI
PBYI
Q4 25
$13.0M
$14.4M
Q3 25
$1.7M
$9.7M
Q2 25
$903.0K
$14.1M
Q1 25
$-6.8M
$3.6M
Q4 24
$2.9M
$15.6M
Q3 24
$878.0K
$11.0M
Q2 24
$4.1M
$1.0M
Q1 24
$-18.3M
FCF Margin
CDLX
CDLX
PBYI
PBYI
Q4 25
25.5%
19.1%
Q3 25
3.7%
17.7%
Q2 25
1.6%
26.8%
Q1 25
-12.1%
7.7%
Q4 24
4.2%
26.4%
Q3 24
1.4%
13.7%
Q2 24
6.5%
2.1%
Q1 24
-29.4%
Capex Intensity
CDLX
CDLX
PBYI
PBYI
Q4 25
0.0%
0.0%
Q3 25
0.0%
0.0%
Q2 25
0.6%
0.0%
Q1 25
0.2%
0.1%
Q4 24
0.2%
0.0%
Q3 24
0.8%
0.0%
Q2 24
0.4%
0.0%
Q1 24
1.0%
0.0%
Cash Conversion
CDLX
CDLX
PBYI
PBYI
Q4 25
Q3 25
1.10×
Q2 25
2.41×
Q1 25
1.21×
Q4 24
Q3 24
0.54×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons